In this interview for The Aids Reader, Micheal Martin, PharmD, addresses why doctors may be reluctant to prescribe abacavir to HIV patients due to risk of hypersensitivity reactions, and explains how the genotype-based dosing guidelines recently published by CPIC can help guide therapy and avoid giving the drug to those who are at risk.
Listen to the podcast
View the CPIC guidelines for HLA-B and abacavir
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clin Pharmacol Ther. 2012 Apr;91(4):734-8.